Parkinson's Disease — CNS Uptake of Intranasal Glutathione
Citation(s)
Bains JS, Shaw CA Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev. 1997 Dec;25(3):335-58. Review.
Cacciatore I, Baldassarre L, Fornasari E, Mollica A, Pinnen F Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. Oxid Med Cell Longev. 2012;2012:240146. doi: 10.1155/2012/240146. Epub 2012 Jun 3. Review.
Coyle JT, Puttfarcken P Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993 Oct 29;262(5134):689-95. Review.
Emir UE, Deelchand D, Henry PG, Terpstra M Noninvasive quantification of T2 and concentrations of ascorbate and glutathione in the human brain from the same double-edited spectra. NMR Biomed. 2011 Apr;24(3):263-9. doi: 10.1002/nbm.1583. Epub 2010 Oct 6.
Gröger A, Chadzynski G, Godau J, Berg D, Klose U Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. Eur Radiol. 2011 Sep;21(9):1962-9. doi: 10.1007/s00330-011-2123
Lee M, Cho T, Jantaratnotai N, Wang YT, McGeer E, McGeer PL Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J. 2010 Jul;24(7):2533-45. doi: 10.1096/fj.09-149997. Epub 2010 Mar 12.
Maher P The effects of stress and aging on glutathione metabolism. Ageing Res Rev. 2005 May;4(2):288-314. Review.
Mischley, L Glutathione Deficiency in Parkinson's Disease: Intranasal Administration as a Method of Augmentation. Journal of Orthomolecular Medicine 26(1):32-36, 2011.
Shils ME OJ, Shike, Moshe Evolution of Knowledge of Essential Nutrients: Conditional Essentiality. Modern Nutrition in Health and Disease. Philadelphia: Lippincott Williams & Wilkins; 2006.
Sofic E, Lange KW, Jellinger K, Riederer P Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett. 1992 Aug 17;142(2):128-30.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
